Semaglutide Mechanism of Action: Complete GLP-1 Receptor Pharmacology and Clinical Evidence Reference

Semaglutide is a glucagon-like peptide-1 receptor agonist that has become one of the most extensively studied compounds in metabolic, cardiovascular, and neuroscience research. Understanding its mechanism of action at the molecular and systems level is essential for interpreting the substantial volume of preclinical and clinical literature on GLP-1 receptor pharmacology. This article provides a detailed reference covering receptor biology, structural pharmacology, downstream signaling cascades, multi-tissue effects, and the principal clinical trial evidence base — with primary reference to peer-reviewed publications.

The compound is a 31-amino-acid synthetic peptide (molecular weight 4,113.6 g/mol; CAS 910463-68-2) derived from the native human GLP-1(7-37) sequence. Two structural modifications distinguish semaglutide from native GLP-1 and from earlier analogues such as liraglutide: an Aib (α-aminoisobutyric acid) substitution at position 8 — which confers resistance to DPP-4 cleavage — and a C18 fatty diacid chain attached via a linker at position 26, which enables reversible albumin binding and accounts for the approximately 168-hour half-life that supports once-weekly dosing in clinical protocols.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

GLP-1 receptor biology

The glucagon-like peptide-1 receptor (GLP-1R) is a class B G-protein-coupled receptor (GPCR) expressed in multiple tissues, including pancreatic beta cells, the hypothalamus and brainstem, the myocardium, the kidneys, and immune cell populations. Native GLP-1 is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion; it has a plasma half-life of approximately 1–2 minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase 24.11. This brevity limits its utility as a research or therapeutic agent in its native form, motivating the development of DPP-4-resistant analogues.

GLP-1R couples primarily to the Gαs protein, stimulating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA) and exchange protein directly activated by cAMP-2 (Epac2), both of which regulate downstream targets in a tissue-specific manner. Receptor activation also recruits β-arrestin pathways, which can signal independently of cAMP and contribute to receptor internalization, desensitization, and — in some cell types — distinct proliferative or protective effects.

The GLP-1R protein shares a characteristic class B GPCR topology: a large N-terminal extracellular domain that contributes to peptide recognition, seven transmembrane helices, and intracellular loops that couple to heterotrimeric G proteins. Cryo-electron microscopy structural studies published from 2017 onward have resolved the receptor–peptide complex at near-atomic resolution, revealing that the N-terminus of GLP-1 binds the extracellular domain while the C-terminal helix engages the transmembrane helical bundle — a "two-domain" binding model that explains both receptor selectivity and the pharmacological differences between short peptide fragments and full-length agonists.

Structural basis for semaglutide's extended half-life

The Aib substitution at position 8 replaces the alanine residue that DPP-4 targets for cleavage, rendering semaglutide DPP-4-resistant. The C18 fatty diacid chain at position 26, attached through a short polyethylene glycol–containing linker, enables high-affinity reversible binding to serum albumin. This albumin association creates a depot effect in circulation: the large albumin–semaglutide complex evades renal filtration, extends plasma residence time, and moderates the rate at which free semaglutide dissociates to engage GLP-1R at target tissues.

Compared with liraglutide — which uses a C16 fatty acid chain and achieves a half-life of approximately 13 hours (requiring once-daily dosing) — semaglutide's longer and more complex fatty acid modification produces markedly more potent albumin binding and the clinically significant extension to once-weekly dosing. For receptor-binding affinity, semaglutide demonstrates higher GLP-1R potency than liraglutide in competitive binding assays, attributed in part to additional sequence modifications that optimize receptor contact.

A third-generation structural variant, oral semaglutide (Rybelsus), co-formulates the peptide with sodium N-[8-(2-hydroxybenzoyl)aminocaprylate] (SNAC), an absorption enhancer that transiently raises gastric pH locally, protects semaglutide from peptic digestion, and promotes transcellular absorption through the gastric mucosa. The mechanism of SNAC-facilitated delivery is distinct from enteric-coated approaches used for other peptide pharmaceuticals. Clinical pharmacokinetic studies in the PIONEER programme demonstrated that oral semaglutide achieved dose-dependent plasma exposure when administered fasting, 30 minutes before the first food or drink of the day, with absolute bioavailability of approximately 1% — substantially lower than subcutaneous injection but sufficient for clinically meaningful GLP-1R agonism at the 7 mg and 14 mg doses studied.

Downstream signaling at GLP-1R

Upon binding semaglutide, GLP-1R undergoes conformational change that activates the Gαs subunit, leading to adenylyl cyclase stimulation and cAMP accumulation. In pancreatic beta cells, the resulting PKA and Epac2 activation converges on several regulatory targets: closure of ATP-sensitive potassium channels (K_ATP), membrane depolarization, and voltage-gated calcium channel opening, producing calcium-dependent insulin exocytosis in a glucose-dependent manner. The glucose dependence is a mechanistically important feature — GLP-1R agonism amplifies insulin secretion only when intracellular glucose metabolism is active, which is why isolated GLP-1R agonism does not drive insulin secretion at fasting glucose concentrations.

Parallel signaling through Epac2 and cAMP-regulated guanine nucleotide exchange factors modulates vesicle priming and fusion machinery, including the SNARE complex proteins that coordinate insulin granule release. Downstream phosphorylation events including Rap1 activation, MAP kinase pathway engagement, and phospholipase C-epsilon stimulation contribute to the full secretory response.

In addition to insulin secretion, GLP-1R activation suppresses glucagon release from alpha cells — both directly (alpha cells express GLP-1R) and via paracrine insulin- and somatostatin-mediated inhibition. The combined effect of augmented insulin and suppressed glucagon lowers hepatic glucose output, contributing to postprandial glycemic regulation in research models.

The Gαs/cAMP pathway also activates the exchange protein Epac1 in vascular and cardiac tissues, where it modulates endothelial nitric oxide synthase (eNOS) phosphorylation, vasodilatation, and inflammatory gene expression. This tissue-specific signaling divergence — Epac2-dominant in pancreatic islets, Epac1-prominent in vascular tissue — is proposed to underlie the mechanistic basis for cardiovascular effects that are partially independent of glycemic effects.

Pancreatic beta cell protection and proliferation

A secondary mechanism of interest in preclinical research is GLP-1R-mediated beta cell cytoprotection and proliferation. cAMP/PKA and PI3K/AKT signaling downstream of GLP-1R activation have been linked in rodent models to anti-apoptotic gene expression changes, upregulation of the transcription factor PDX-1, and modest increases in beta cell mass. These effects have been demonstrated in streptozotocin-induced diabetic rodent models, diet-induced obesity models, and isolated islet preparations.

The degree to which these proliferative and cytoprotective findings translate to primate or human biology remains an active research question. Non-human primate studies have shown GLP-1R agonist effects on beta cell function but less consistent evidence of mass expansion than observed in rodents. Interpretive caution is warranted when extrapolating rodent beta cell mass data to human physiology.

Central nervous system and appetite regulation

GLP-1R is expressed in the arcuate nucleus of the hypothalamus, the nucleus of the solitary tract (NTS), the dorsal motor nucleus of the vagus, and the area postrema — brain regions that integrate peripheral metabolic signals and regulate food intake and energy expenditure. Preclinical studies using central administration of GLP-1 analogues have established that GLP-1R activation in these nuclei reduces food intake through a combination of appetite suppression and enhanced satiety signaling.

Semaglutide crosses the blood-brain barrier, particularly at circumventricular organs that lack a complete barrier. Research in rodents and non-human primates shows that centrally acting GLP-1R agonism reduces meal size, prolongs inter-meal intervals, and lowers preference for high-calorie food in preference paradigms. Functional neuroimaging studies in humans have documented reduced activation in reward-associated brain regions in response to food cues following GLP-1R agonist administration, consistent with an effect on reward valuation rather than purely homeostatic satiety.

Central GLP-1R signaling is also implicated in gastric emptying modulation via the vagal nerve. Semaglutide slows gastric emptying rate, an effect that contributes to reduced postprandial glucose excursions and to the nausea commonly reported during dose escalation — the nausea reflex is mediated at least partly by area postrema GLP-1R activation.

A case report published in 2026 (PMID 42027588) documented reversible central respiratory depression — characterized by nocturnal hypercapnia (PaCO₂ 56 mmHg, pH 7.33) without sleep-disordered breathing — in an individual following semaglutide dose escalation to 1 mg per week. The finding implicates GLP-1R expression in the nucleus tractus solitarius and dorsal motor nucleus of the vagus in respiratory chemoreceptor function. Symptoms resolved within three weeks of discontinuation.

Research into potential neuroprotective effects of GLP-1R agonism is ongoing. GLP-1R expression has been confirmed in hippocampal neurons, dopaminergic neurons of the substantia nigra, and cortical regions. Preclinical models of Parkinson's disease (6-OHDA and MPTP mouse models) have demonstrated that GLP-1R agonism attenuates dopaminergic neuron loss and improves motor performance. A Phase 2 randomized trial of semaglutide in Parkinson's disease (ANZCTR12623000241​651) is underway; results are not yet available as of this writing.

Glycemic effects and the SUSTAIN clinical trial programme

The SUSTAIN programme comprises nine large Phase 3 randomized controlled trials evaluating subcutaneous semaglutide (0.5 mg and 1.0 mg weekly) in populations with type 2 diabetes. Key findings relevant to the mechanistic interpretation of GLP-1R agonism at scale:

SUSTAIN-1 (26 weeks, monotherapy vs placebo): HbA1c reductions of −1.45% (0.5 mg) and −1.55% (1.0 mg) from a mean baseline of approximately 8.1%. Fasting plasma glucose reductions of approximately 2.5–2.7 mmol/L. Body weight reductions of −3.73 kg (0.5 mg) and −4.53 kg (1.0 mg).

SUSTAIN-2 (56 weeks, add-on vs sitagliptin): Semaglutide 1.0 mg produced −1.5% HbA1c vs −0.9% for sitagliptin, demonstrating the superior potency of a GLP-1R agonist with extended half-life vs DPP-4 inhibition.

SUSTAIN-3 (56 weeks, vs exenatide once-weekly): Semaglutide 1.0 mg produced −1.5% HbA1c vs −0.9% for exenatide, and weight reductions of −5.6 kg vs −1.9 kg — attributable to the higher GLP-1R occupancy achieved by semaglutide's superior albumin-binding half-life extension.

SUSTAIN-4 (30 weeks, vs insulin glargine): Semaglutide produced lower HbA1c with significantly greater weight reduction (−5.17 kg vs +1.15 kg for insulin glargine), illustrating the mechanistically distinct metabolic profile of GLP-1R agonism vs insulin-based therapy.

SUSTAIN-6 (2-year CVOT vs placebo): 3,297 participants at high cardiovascular risk. Primary endpoint: 3-point MACE (cardiovascular death, nonfatal MI, nonfatal stroke). Semaglutide showed a 26% relative risk reduction vs placebo (HR 0.74; 95% CI 0.58–0.95; p < 0.001 for non-inferiority; p = 0.02 for superiority). Nonfatal stroke HR was 0.61 (95% CI 0.38–0.99). The cardiovascular benefit was observed despite a relatively short duration, suggesting mechanisms beyond glycemic control — likely the combination of weight loss, blood pressure reduction, and direct vascular GLP-1R signaling (PMID 27633186).

Obesity and weight management: the STEP trial programme

The STEP (Semaglutide Treatment Effect in People with Obesity) programme evaluated semaglutide 2.4 mg subcutaneously once-weekly (a higher dose than the SUSTAIN programme) in participants with obesity or overweight with at least one weight-related comorbidity.

STEP 1 (68 weeks, vs placebo; n=1,961; no diabetes): Mean body weight reduction of −14.9% (semaglutide 2.4 mg) vs −2.4% (placebo). 86.4% of participants in the semaglutide group achieved ≥5% weight loss; 69.1% achieved ≥10%; 50.5% achieved ≥15%. These outcomes are benchmarks for understanding the upper range of GLP-1R agonist effect on energy homeostasis in research models (PMID 33567185).

STEP 2 (68 weeks; type 2 diabetes population): Mean weight reduction −9.6% (2.4 mg) vs −3.4% (placebo), with HbA1c reduction −1.6% vs −0.4%.

STEP 3 (68 weeks; intensive behavioral intervention background): −16.0% weight reduction with semaglutide vs −5.7% with placebo, demonstrating additive effects between GLP-1R agonism and behavioral modification.

STEP 4 (withdrawal trial, 68 weeks): Participants who responded to semaglutide over 20 weeks then randomized to continue or switch to placebo. Continued semaglutide maintained −17.4% weight loss at week 68; placebo-switchers regained weight (mean +6.9% from randomization). This weight regain on discontinuation is consistent with GLP-1R agonism acting as a pharmacological substitute for a hormonal signal, not producing durable metabolic reprogramming — a finding with significant implications for long-term research design.

STEP 5 (2 years): −15.2% weight reduction maintained at 104 weeks, confirming durability of effect with continued GLP-1R agonism.

Cardiovascular outcomes beyond CVOT: the SELECT trial

The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity; NCT03574597) enrolled 17,604 participants with established cardiovascular disease but without diabetes — a mechanistically important distinction from the SUSTAIN-6 population, as it isolated cardiovascular effects from glycemic improvement contributions.

Published in The New England Journal of Medicine in 2023 (PMID 37632470), SELECT demonstrated a 20% reduction in the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (HR 0.80; 95% CI 0.72–0.90; p < 0.001) over a mean follow-up of 39.8 months. The cardiovascular benefit emerged in the absence of meaningful differences in glycated hemoglobin between groups, implying mechanisms attributable to weight reduction and direct vascular GLP-1R agonism rather than glycemic correction. This finding has substantial implications for understanding which components of GLP-1R downstream signaling drive cardiovascular risk modification.

Secondary endpoints in SELECT documented meaningful reductions in heart failure hospitalization and improvements in kidney function biomarkers (eGFR trajectory), further supporting a direct renal GLP-1R role.

Oral semaglutide: the PIONEER programme

The PIONEER programme evaluated oral semaglutide (SNAC-formulated; 7 mg, 14 mg) across ten Phase 3 trials in type 2 diabetes. Key mechanistic findings:

PIONEER 1 (monotherapy, 26 weeks): HbA1c reductions of −0.8% (7 mg) and −1.4% (14 mg) vs −0.1% (placebo). The dose-response confirms that the SNAC-enabled gastric absorption mechanism delivers sufficient systemic semaglutide to engage pancreatic GLP-1R meaningfully even at the low absolute bioavailability (~1%) characteristic of the oral route.

PIONEER 4 (vs subcutaneous liraglutide 1.2 mg and placebo, 52 weeks): Oral semaglutide 14 mg achieved −1.2% HbA1c vs −1.1% for subcutaneous liraglutide — demonstrating that SNAC-formulated oral delivery can match a parenteral GLP-1R agonist's efficacy despite the bioavailability gap, by virtue of the higher administered dose and longer semaglutide intrinsic half-life.

PIONEER 6 (CVOT, median 15.9 months): HR 0.79 (95% CI 0.57–1.11; non-inferiority met) for 3-point MACE, consistent with the subcutaneous SUSTAIN-6 cardiovascular findings.

The PIONEER programme's importance in mechanistic research is that it confirms the GLP-1R pharmacological effects described above are not route-of-administration-dependent — central and peripheral GLP-1R agonism occurs whether the free semaglutide is delivered subcutaneously (sustained plasma depot) or via oral gastric absorption (more variable peak levels). The primary pharmacodynamic driver is GLP-1R occupancy, not delivery route.

Renal research findings

GLP-1R is expressed in glomerular endothelial cells, podocytes, proximal tubular cells, and mesangial cells. Preclinical mechanistic data support a role for direct renal GLP-1R activation in sodium–glucose cotransporter regulation, reduction of inflammatory cytokine expression (IL-6, TNF-α) in tubular cells, and attenuation of transforming growth factor-beta (TGF-β)-driven fibrotic signaling in mesangial cells exposed to high-glucose conditions.

The FLOW trial (NCT03819153), a dedicated renal outcomes trial of semaglutide 1.0 mg in type 2 diabetes with chronic kidney disease, was stopped early in late 2023 for efficacy. The primary endpoint of kidney disease progression, cardiovascular death, or renal death showed significant benefit favoring semaglutide. The mechanistic basis for these renal effects is understood as a composite of improved hemodynamic parameters (blood pressure, intraglomerular pressure), reduction of systemic and local inflammatory signaling through GLP-1R agonism in renal tissue, and indirect benefits from weight-mediated improvements in metabolic syndrome parameters.

A 2026 publication (PMID 41655226) reported that semaglutide — alongside tirzepatide — was associated with significant bone mineral density (BMD) decline at the total hip and femoral neck over a median of 17 months (n=510), a finding consistent with the established relationship between GLP-1R agonist-mediated weight loss and reductions in bone-loading mechanical stimulus. This is a reminder that GLP-1R's multi-system distribution produces effects extending beyond the classical metabolic compartments, and that skeletal biology is an active area of GLP-1R research.

Cardiovascular and vascular research findings

GLP-1R expression in cardiomyocytes, endothelial cells, and vascular smooth muscle has motivated research into semaglutide's cardiovascular effects independent of its metabolic actions. The receptor's Gαs/cAMP signaling in cardiac tissue is proposed to modulate myocardial contractility, reduce ischemia-reperfusion injury, and attenuate inflammatory signaling. Retrospective cohort data across GLP-1 receptor agonists as a class — including liraglutide, semaglutide, and dulaglutide — have documented associations with reduced risk of myocardial infarction (HR 0.65), ischemic stroke (HR 0.78), and acute kidney injury (HR 0.68) in large real-world populations with type 2 diabetes and diabetic retinopathy (PMID 42025665).

Mechanistic proposals for the vascular benefit include: (1) eNOS phosphorylation and nitric oxide production in endothelial cells via Epac1/PI3K signaling, improving endothelial function; (2) reduction of VCAM-1 and ICAM-1 expression, limiting monocyte adhesion and plaque inflammatory activity; (3) direct cardiomyocyte protection through PKA-mediated phosphorylation of phospholamban and troponin I, improving diastolic relaxation; (4) atrial natriuretic peptide secretion stimulation, contributing to natriuresis and preload reduction.

Structural comparison: semaglutide, liraglutide, tirzepatide, and retatrutide

Understanding semaglutide's selective GLP-1R mechanism is important for isolating GLP-1R-specific contributions in comparative research designs.

Feature	Native GLP-1	Liraglutide	Semaglutide	Tirzepatide	Retatrutide
Receptor targets	GLP-1R	GLP-1R	GLP-1R	GLP-1R + GIPR	GLP-1R + GIPR + GCGR
Route	N/A	Subcutaneous (daily)	SC (weekly) or Oral	Subcutaneous (weekly)	Subcutaneous (weekly)
Half-life	~1–2 min	~13 hours	~168 hours	~5 days	~6 days
Fatty acid chain	None	C16	C18 diacid	C20 diacid	C20 diacid
DPP-4 resistance	No	Partial (C16 binding)	Full (Aib-8)	N/A (non-peptide GIP portion)	N/A
Peak HbA1c reduction (Phase 3)	—	~1.2–1.5%	~1.5–1.8%	~2.0–2.3%	~2.0% (Phase 2)
Peak weight reduction (obesity)	—	~5–7%	~15% (2.4 mg, STEP 1)	~20–22% (SURMOUNT)	~24% (TRIUMPH-1, Phase 2)

The expanding receptor target profile from semaglutide → tirzepatide → retatrutide produces progressively greater weight loss in comparative trials, with GIPR co-agonism adding appetite-independent energy expenditure effects and GCGR co-agonism adding thermogenic and hepatic lipid oxidation contributions. A 2026 network meta-analysis (PMID 41664890) confirmed tirzepatide's superiority over semaglutide for both HbA1c and body weight outcomes in the type 2 diabetes population. For research designs seeking GLP-1R-isolated effects, semaglutide remains the pharmacological reference standard. The tirzepatide mechanism of action article and retatrutide triple agonist article detail the additive receptor mechanisms.

Regulatory status

Semaglutide holds FDA approval for two indications: type 2 diabetes management (Ozempic, subcutaneous; Rybelsus, oral) and chronic weight management (Wegovy, subcutaneous). These approvals are for specific branded pharmaceutical formulations produced by Novo Nordisk under defined Good Manufacturing Practice conditions. Compounding of semaglutide under 503A or 503B status has been subject to FDA regulatory action; the current status of these pathways is covered in the FDA 503B GLP-1 exclusion proposal article.

For full compound data including molecular formula, chemistry details, and the extended study registry, see the semaglutide library profile.

Frequently asked questions

What is semaglutide's mechanism of action in simple terms? Semaglutide binds and activates the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor expressed in the pancreas, brain, heart, kidney, and other tissues. In the pancreas, GLP-1R activation increases insulin secretion in a glucose-dependent manner and suppresses glucagon. In the hypothalamus and brainstem, it reduces appetite and slows gastric emptying. In the cardiovascular system, it modulates vascular inflammation and endothelial function. The compound's extended ~168-hour half-life — achieved via DPP-4-resistant Aib-8 substitution and albumin-binding C18 fatty diacid chain — allows once-weekly dosing.

How does semaglutide differ mechanistically from liraglutide? Both target GLP-1R selectively, but semaglutide uses a longer C18 fatty diacid chain (vs liraglutide's C16 fatty acid) that produces stronger albumin binding and a ~168-hour half-life vs ~13 hours. Semaglutide also incorporates an Aib substitution at position 8 for complete DPP-4 resistance. These structural differences translate to significantly greater weight loss and superior GLP-1R potency in head-to-head studies (PIONEER 4, SUSTAIN vs liraglutide comparator arms). The semaglutide vs liraglutide comparison article covers pharmacokinetic and clinical trial differences in detail.

What does the SELECT trial demonstrate about semaglutide's mechanism? SELECT (PMID 37632470; n=17,604) showed a 20% relative risk reduction in major adverse cardiovascular events in participants with established cardiovascular disease but without diabetes. Since glycemic differences between groups were minimal, the benefit is attributed to weight loss and direct cardiovascular GLP-1R agonism — including eNOS-mediated endothelial improvement, reduction of vascular inflammatory markers, and cardiomyocyte protective signaling — rather than to glycemic correction alone.

How does oral semaglutide work differently from injected semaglutide? Oral semaglutide (Rybelsus) is co-formulated with SNAC (sodium N-[8-(2-hydroxybenzoyl)aminocaprylate]), an absorption enhancer that transiently raises local gastric pH and facilitates transcellular absorption through the gastric mucosa. Absolute bioavailability is approximately 1%, substantially lower than the subcutaneous route, but the higher oral dose (7 mg, 14 mg) and semaglutide's intrinsically long half-life produce clinically meaningful GLP-1R occupancy. PIONEER 4 demonstrated that oral semaglutide 14 mg matched subcutaneous liraglutide 1.2 mg for HbA1c reduction.

Is semaglutide's weight loss effect primarily central or peripheral? Research supports a composite mechanism. Centrally: GLP-1R agonism in the arcuate nucleus, NTS, and area postrema reduces food intake by suppressing appetite and reward-driven eating, and slows gastric emptying via vagal circuits. Peripherally: GLP-1R agonism in adipose tissue and the liver may modulate lipid metabolism and energy substrate utilization. The STEP 4 withdrawal data (weight regain on discontinuation) indicate that the central appetite-suppressive signal is not durably reprogrammed by treatment — it is pharmacologically maintained.

What are the renal effects of semaglutide in research models? GLP-1R expression in renal tissue (podocytes, tubular cells, glomerular endothelium) is associated with anti-inflammatory, anti-fibrotic, and natriuretic effects in preclinical models. The FLOW dedicated renal outcomes trial (NCT03819153) was stopped early for efficacy, demonstrating significant reductions in kidney disease progression in type 2 diabetes with CKD. The SELECT trial secondary endpoints also showed favorable eGFR trajectory. Mechanistically, proposed pathways include reduced intraglomerular pressure, TGF-β pathway attenuation in mesangial cells, and improved systemic hemodynamics.

Cited studies

• PMID 27633186 — Marso SP et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." N Engl J Med. 2016;375:1834–1844. (SUSTAIN-6 CVOT). https://doi.org/10.1056/NEJMoa1607141

• PMID 33567185 — Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384:989–1002. (STEP 1). https://doi.org/10.1056/NEJMoa2032183

• PMID 37632470 — Lincoff AM et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. 2023;389:2221–2232. (SELECT). https://doi.org/10.1056/NEJMoa2307563

• PMID 31475794 — Pratley R et al. "Oral Semaglutide versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4)." Lancet. 2019;394:39–50. https://doi.org/10.1016/S0140-6736(19)31271-1

• PMID 41655226 — "Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures." PubMed, June 2026. (BMD findings, n=510, median 17 months).

• PMID 41664890 — "Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide." Journal of Diabetes, June 2026. (Tirzepatide superior for HbA1c and weight outcomes).

• PMID 42027588 — "Unexplained hypercapnia with normal pulmonary evaluation in a patient receiving semaglutide: a diagnostic challenge." Case Reports, 2026.

• PMID 42025665 — "Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy." Ophthalmology, 2026.

---

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.